Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Pharmacology

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/bph.12344PMID 23962094PMCID PMC3799588
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.

  2013influential reference
• Angiopoietins in angiogenesis.

  2013influential reference
• Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.

  2013cited by this paper
• Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2013cited by this paper
• Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

  2013cited by this paper
• The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.

  2013influential reference
• Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

  2013cited by this paper
• Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.

  2013influential reference
• Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

  2013influential reference
• Hypoxia-inducible Factor-1 (HIF-1)-independent Hypoxia Response of the Small Heat Shock Protein hsp-16.1 Gene Regulated by Chromatin-remodeling Factors in the Nematode Caenorhabditis elegans*

  2012cited by this paper
• Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  2012cited by this paper
• Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

  2012influential reference
• Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

  2012cited by this paper
• A phase I/II trial of vandetanib for patients with recurrent malignant glioma.

  2012cited by this paper
• Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

  2012cited by this paper
• AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

  2012influential reference
• Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

  2012cited by this paper
• Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis

  2012influential reference
• Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

  2012cited by this paper
• Discovery and development of N-cadherin antagonists

  2012cited by this paper
• Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

  2012influential reference
• Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

  2012cited by this paper
• A preclinical and clinical review of aflibercept for the management of cancer.

  2012cited by this paper
• Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

  2012cited by this paper
• Bevacizumab advanced melanoma (BEAM) was a positive trial.

  2012cited by this paper
• Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?

  2012cited by this paper
• Side effects of anti-angiogenic drugs.

  2012cited by this paper
• Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.

  2012cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

  2012cited by this paper
• Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?

  2012cited by this paper
• The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

  2012cited by this paper
• Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

  2012cited by this paper
• Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

  2012cited by this paper
• Intussusceptive microvascular growth in tumors.

  2012cited by this paper
• Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

  2012cited by this paper
• Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?

  2012cited by this paper
• Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.

  2012cited by this paper
• Tumor Angiogenesis as a Target for Dietary Cancer Prevention

  2011cited by this paper
• Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

  2011cited by this paper
• Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.

  2011cited by this paper
• Endothelial nitric oxide synthase controls the expression of the angiogenesis inhibitor thrombospondin 2

  2011cited by this paper
• Cancer associated fibroblasts: the dark side of the coin.

  2011cited by this paper
• Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.

  2011cited by this paper
• Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

  2011influential reference
• Lipid mediators in life science.

  2011cited by this paper
• A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

  2011influential reference
• Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

  2011cited by this paper
• (−)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling–Mediated Angiogenesis

  2011cited by this paper
• Sphingosine‐1‐phosphate antibodies as potential agents in the treatment of cancer and age‐related macular degeneration

  2011cited by this paper
• Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

  2011influential reference
• Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

  2011cited by this paper
• FGF-dependent regulation of VEGF receptor 2 expression in mice.

  2011cited by this paper
• Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

  2011cited by this paper
• M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis

  2011cited by this paper
• Antiangiogenesis enhances intratumoral drug retention.

  2011cited by this paper
• αV integrins in angiogenesis and cancer.

  2011cited by this paper
• Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

  2011cited by this paper
• Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer

  2011cited by this paper
• Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

  2011cited by this paper
• Nanoparticulate Delivery System Targeted to Tumor Neovasculature for Combined Anticancer and Antiangiogenesis Therapy

  2011cited by this paper
• PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

  2011cited by this paper
• Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence.

  2011cited by this paper
• Tumour macrophages as potential targets of bisphosphonates

  2011cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cited by this paper
• Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.

  2010cited by this paper
• Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

  2010cited by this paper
• PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

  2010cited by this paper
• Maintenance therapy in colon cancer.

  2010cited by this paper
• Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts

  2010cited by this paper
• A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer

  2010cited by this paper
• Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

  2010influential reference
• The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways

  2010cited by this paper
• Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

  2010influential reference
• Eicosanoids and cancer

  2010influential reference
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-κB Activity

  2010influential reference
• Targeting the tumour vasculature: insights from physiological angiogenesis

  2010cited by this paper
• Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

  2010cited by this paper
• Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

  2010cited by this paper
• Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

  2010cited by this paper
• Targeting of drugs and nanoparticles to tumors

  2010cited by this paper
• METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER

  2010cited by this paper
• Resveratrol Suppresses Colitis and Colon Cancer Associated with Colitis

  2010cited by this paper
• Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

  2010influential reference
• Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.

  2010cited by this paper
• Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

  2009cited by this paper
• Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer.

  2009cited by this paper
• An overview of small-molecule inhibitors of VEGFR signaling

  2009cited by this paper
• Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy

  2009influential reference
• Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

  2009cited by this paper
• JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

  2009influential reference
• PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment

  2009cited by this paper
• Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib

  2009influential reference
• Endogenous inhibitors of angiogenesis: a historical review.

  2009influential reference
• Targeting of Tumor Blood Vessels: A Phage-Displayed Tumor-Homing Peptide Specifically Binds to Matrix Metalloproteinase-2-Processed Collagen IV and Blocks Angiogenesis In vivo

  2009cited by this paper

• The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease

  2025cites this paper
• Synthesis and evaluation of tellurophene–BODIPY photosensitizers appended to estradiol

  2025cites this paper
• Natural anticancer agents: prospection of medicinal and aromatic plants in modern chemoprevention and chemotherapy

  2025cites this paper
• Intervention of biophysical effects generated by self-assembly peptides in tumor progression.

  2025cites this paper
• Protopine as a Potential Breast Cancer Therapeutic: A Computational Study Targeting PIK3CA and Cancer Networks

  2025cites this paper
• Effectiveness of sesame oil and melatonin on P53 level in spinal cord injury of rat menopausal model.

  2025cites this paper
• DLL4/VEGF bispecific molecularly imprinted nanomissile for robust tumor therapy.

  2025cites this paper
• Targeting angiogenesis in cancer therapy: lessons learned and paths forward.

  2025cites this paper
• AZ-628 sensitizes donafenib in hepatocellular carcinoma by targeting tyrosine kinase pathway and ferroptosis

  2025cites this paper
• Multi-omics based consensus subtypes, development of prognostic signature, and identification of INHBB as a potential therapeutic target in colorectal cancer

  2025cites this paper
• Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects.

  2025cites this paper
• Anti-neoangiogenic nanodelivery systems: advances in tumor-based and ophthalmic disease research.

  2025cites this paper
• Type IV collagen derived non-collagenous domain α6 (IV) NC1 and its derivative fragments inhibit endothelial cell proliferation and attenuates in-vivo chorioallantoic membrane angiogenesis

  2025cites this paper
• The polyphenolic compound, α-conidendrin, exerts anti-colon cancer and anti-angiogenic effects by targeting several signaling molecules

  2025cites this paper
• Isolation, structural characterization of natural chondroitin sulfate oligosaccharides and their binding study with anti-angiogenic factors.

  2025cites this paper
• Smart release injectable hydrogel co-loaded with liposomal combretastatin A4 and doxorubicin nanogel for local combinational drug delivery: A preclinical study.

  2025cites this paper
• The potential application of stroma modulation in targeting tumor cells: focus on pancreatic cancer and breast cancer models.

  2025cites this paper
• Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

  2024cites this paper
• Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip

  2024cites this paper
• The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer

  2024cites this paper
• Drug-Linker Constructs Bearing Unique Dual-Mechanism Tubulin Binding Payloads Tethered through Cleavable and Non-Cleavable Linkers.

  2024cites this paper
• Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma

  2024cites this paper
• Noscapine modulates hypoxia‐induced angiogenesis and hemodynamics: Insights from a zebrafish model investigation

  2024cites this paper
• Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications

  2024cites this paper
• Investigating the mechanism of tricyclic decyl benzoxazole -induced apoptosis in liver Cancer cells through p300-mediated FOXO3 activation.

  2024cites this paper
• Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment

  2024cites this paper
• Anti‐angiogenesis in colorectal cancer therapy

  2024cites this paper
• Promising Phytoconstituents in Antiangiogenesis Drug Development

  2024cites this paper
• Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.

  2024cites this paper
• Furan- and Furopyrimidine-Based Derivatives: Synthesis, VEGFR-2 Inhibition, and In Vitro Cytotoxicity.

  2024cites this paper
• A phase II randomized, double-blind, placebo-controlled study of Nuvastatic (C50SEW505OESA), a standardized rosmarinic acid-rich polymolecular botanical extract formulation to reduce cancer-related fatigue in patients with solid tumors

  2024cites this paper
• A weighted combination of reproducing kernel particle shape functions with cardinal functions of scalable polyharmonic spline radial kernel utilized in Galerkin weak form of a mathematical model related to anti-angiogenic therapy

  2024cites this paper
• Design and Synthesis of Novel N-Benzylidene Derivatives of 3-Amino-4-imino-3,5-dihydro-4H-chromeno[2,3-d]pyrimidine under Microwave, In Silico ADME Predictions, In Vitro Antitumoral Activities and In Vivo Toxicity

  2024cites this paper
• Emerging immunologic approaches as cancer anti-angiogenic therapies

  2024cites this paper
• Relationship Between Aspirin Use and Site-Specific Colorectal Cancer Risk Among Individuals With Metabolic Comorbidity

  2024cites this paper
• New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis.

  2023cites this paper
• Flavonoids: As omnipotent candidates for cancer management

  2023cites this paper
• Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment—An Overview

  2023cites this paper
• The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know

  2023cites this paper
• Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors

  2023cites this paper
• High glucose-induced IL-7/IL-7R upregulation of dermal fibroblasts inhibits angiogenesis in a paracrine way in delayed diabetic wound healing

  2023cites this paper
• Research Progress of Anti-Angiogenic Drugs in First-Line Treatment of Small Cell Lung Cancer

  2023cites this paper
• Extracellular Vesicles as Delivery Shippers for Noncoding RNA-Based Modulation of Angiogenesis: Insights from Ischemic Stroke and Cancer.

  2023cites this paper
• Anti-Angiogenic Effect of Clerodendreme inerme Leaves Extract

  2023cites this paper
• Mechanisms of Physiological Angiogenesis

  2023cites this paper
• Inhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways

  2023cites this paper
• Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status

  2023cites this paper
• The impact of gut microbiota on vascularization of the small intestine

  2023cites this paper
• Prostate Cancer Microvascular Routes: Exploration and Measurement Strategies

  2023cites this paper
• Antitumor Activity of Selenium in Ehrlich Ascites Carcinoma Bearing Mice

  2023cites this paper
• Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma

  2023cites this paper
• PDGFRA exhibits potential as an Indicator of angiogenesis within the tumor microenvironment and is up-regulated in BLCA.

  2023cites this paper
• In Vitro Antioxidant Activity, Pharmacognostical Evaluation, HPTLC and FTIR Fingerprinting of Phyllanthus Acidus L. Stem Bark Extract for Better Application in Phytotherapy

  2023cites this paper
• Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery.

  2023cites this paper
• Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non‐squamous non‐small cell lung cancer after bevacizumab treatment

  2023cites this paper
• Dually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment

  2023cites this paper
• Identification of angiogenesis-related subtypes, the development of prognostic models, and the landscape of tumor microenvironment infiltration in colorectal cancer

  2023cites this paper
• Anti-angiogenic drugs in cancer therapeutics: a review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential

  2022cites this paper
• Metastasis prevention: targeting causes and roots

  2022cites this paper
• The anti-angiogenic effect of atorvastatin loaded exosomes on glioblastoma tumor cells: An in vitro 3D culture model.

  2022cites this paper
• Chorioallantoic membrane tumor models highlight the effects of cisplatin compounds in oral carcinoma treatment

  2022cites this paper
• Targeting Angiogenic Factors for the Treatment of Medulloblastoma

  2022cites this paper
• HiTIMED: hierarchical tumor immune microenvironment epigenetic deconvolution for accurate cell type resolution in the tumor microenvironment using tumor-type-specific DNA methylation data

  2022cites this paper
• Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches

  2022cites this paper
• Anti-Angiogenetic and Anti-Lymphangiogenic Effects of a Novel 2-Aminobenzimidazole Derivative, MFB

  2022cites this paper
• WNK1–OSR1 Signaling Regulates Angiogenesis-Mediated Metastasis towards Developing a Combinatorial Anti-Cancer Strategy

  2022cites this paper
• Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer

  2022cites this paper
• Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

  2022cites this paper
• Ehrlich Ascites carcinoma mice model for studying liver inflammation and fibrosis

  2022cites this paper
• Medication‐related osteonecrosis of the jaw: A literature review and update

  2022cites this paper
• A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer

  2022cites this paper
• Application of Nano-particulate drug delivery systems to deliver therapeutic agents into cancer cells

  2022cites this paper
• Molecular subtypes, clinical significance, and tumor immune landscape of angiogenesis-related genes in ovarian cancer

  2022cites this paper
• Evolving therapeutic proteins to precisely kill cancer cells.

  2022cites this paper
• Krill oil supplementation reduces the growth of CT-26 orthotopic tumours in Balb/c mice

  2022cites this paper
• Inhibitory effect of ginsenglactone A from Panax ginseng on the tube formation of human umbilical vein endothelial cells and migration of human ovarian cancer cells

  2022cites this paper
• Antiangiogenic drugs as chemosensitizers in hematological tumors

  2022cites this paper
• Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

  2022cites this paper
• Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab

  2022cites this paper
• Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies

  2022cites this paper
• Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment

  2022cites this paper
• Molecular targeted therapy for anticancer treatment

  2022cites this paper
• Impact of Polypyridyl Ru Complexes on Angiogenesis—Contribution to Their Antimetastatic Activity

  2022cites this paper
• Generation of Augmented Capillary Network Optical Coherence Tomography Image Data of Human Skin for Deep Learning and Capillary Segmentation

  2021cites this paper
• Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer

  2021cites this paper
• Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature

  2021cites this paper
• Tratamento da osteonecrose dos maxilares associada ao uso de medicamentos - revisão de literatura

  2021cites this paper
• Bioactive Molecules of Endophytic Fungi and Their Potential in Anticancer Drug Development

  2021cites this paper
• Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

  2021cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.

  2021cites this paper
• Current Ovarian Cancer Maintenance Strategies and Promising New Developments

  2021cites this paper
• Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib

  2021cites this paper
• Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation

  2021cites this paper
• Targeting the acetylation signaling pathway in cancer therapy.

  2021cites this paper
• Bioactive Molecules of Endophytic Fungi and Their Potential in Anticancer Drug Development

  2021cites this paper
• Nephrotoxicity induced by vascular endothelial growth factor inhibitors

  2021cites this paper
• Quercetin Inhibits Colorectal Cancer Cells Induced-Angiogenesis in Both Colorectal Cancer Cell and Endothelial Cell through Downregulation of VEGF-A/VEGFR2

  2021cites this paper
• Targeting Angiogenesis for Colorectal Cancer Therapy

  2021cites this paper
• Gold nanocrystals as potential inhibitors of tumor angiogenesis: implications in diagnosis and drug delivery

  2021cites this paper